The EveryPrem Project: Evaluating the INTER-NDA for Standardized Neurodevelopmental Screening at 2 Years of Age for Children Born Preterm.
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Prematurity
- 发起方
- Giancarlo Natalucci
- 入组人数
- 800
- 试验地点
- 1
- 主要终点
- INTER-NDA domain scores and centiles
- 状态
- 进行中（未招募）
- 最后更新
- 18天前
概览
简要总结
Neurodevelopmental follow-up of infants at high-risk such as preterm born is necessary in order to early detect impairments and early start a supportive/therapeutic intervention. Valid tools should be available for screening infants with developmental problems even where resources are limited. Such screening would ensure an adequate medical care during and after hospital discharge as well as evidence-based parental pre- and postnatal counselling. While in Switzerland, these tools are specifically needed for the neurodevelopmental surveillance of moderate to late pretem born infants, in low- and mid-income countries, they are needed to monitor the whole population of preterm born infants.
To fill this important gap, the present study aims to determine whether it is feasible to extend neurodevelopmental screening (currently offered to only a very small part of children born preterm), by using a new cost-effective neurodevelopmental assessment, the INTERGROWTH-21st Neurodevelopment Assessment (INTER-NDA, www.inter-nda.com Assessment) at age 2 years.
详细描述
The pirmary objectives of the study are: 1. In very preterm born infants (born \< 32 weeks' gestation) \- To assess the concurrent validity of the INTER-NDA with the Bayley-III\[13\] at 2 years of corrected age in VPT infants. 2. In moderate to late preterm infants (born between 32 and 36 weeks' gestation) - To screen neurodevelopment performances at corrected 2 years of corrected age in MLPT infants by means of the INTER-NDA and to compare values with international INTER-NDA standard values.
研究者
Giancarlo Natalucci
Principal Investigator
University of Zurich
入排标准
入选标准
- •Former patient of the Department of Neonatology of the University Hospital Zurich
- •Born between 01.01.2019 and 31.12.2021, i.e. aged 18 to 30 months at the time of the research visit
- •Gestational age below 370/7 weeks
- •Parent consent
排除标准
- •Genetically defined syndrome (including chromosomal aberration) or inborn error of metabolism adversely influencing life expectancy or neurodevelopment.
- •Major congenital malformations requiring surgical correction or potentially affecting neurodevelopmental outcome.
- •Hypoxic ischemic encephalopathy after perinatal asphyxia defined as grade 2 or 3 according to Sarnat and Sarnat\[19\].
- •Neonatal drug withdrawal syndrome or known maternal substance consumption of following illicit drugs during pregnancy: cocaine, heroin, Lysergic acid diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (ecstasy), phencyclidine (PCP), and other amphetamine/methamphetamine.
- •Children of parents who are not speaking German
结局指标
主要结局
INTER-NDA domain scores and centiles
时间窗: At age 18 to 20 months; test duration 15 to 20 minutes.
The INTERGROWTH-21st Neurodevelopment Assessment (INTER-NDA) is new cost-effective neurodevelopmental assessment for 2-year old infants.